Celldex Therapeutics (CLDX) Total Liabilities (2010 - 2026)

Celldex Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $55.0 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 50.8% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (up 50.8% YoY), while the FY2025 annual figure was $55.8 million, up 23.12% from the prior year.
• Total Liabilities was $55.0 million for Q1 2026 at Celldex Therapeutics, down from $55.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $55.8 million in Q4 2025 to a low of $21.8 million in Q2 2023.
• Historically, Total Liabilities has averaged $35.7 million across 5 years, with a median of $36.5 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 70.05% in 2022, then plunged 42.5% in 2023.
• A 5-year view of Total Liabilities shows it stood at $26.5 million in 2022, then jumped by 37.41% to $36.5 million in 2023, then increased by 24.36% to $45.3 million in 2024, then increased by 23.12% to $55.8 million in 2025, then fell by 1.42% to $55.0 million in 2026.
• The last three Total Liabilities figures came in at $55.0 million (Q1 2026), $55.8 million (Q4 2025), and $50.1 million (Q3 2025), per Business Quant data.